Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts).
K. L. Tedesco
Research Funding - PharmaMar
J. L. Blum
No relevant relationships to disclose
A. Goncalves
No relevant relationships to disclose
J. Lubinski
No relevant relationships to disclose
C. R. C. Osborne
No relevant relationships to disclose
P. Lardelli
Employment or Leadership Position - PharmaMar
Stock Ownership - Zeltia
J. C. Tercero
Employment or Leadership Position - PharmaMar
Stock Ownership - Zeltia
A. Florez
Employment or Leadership Position - PharmaMar
F. A. Holmes
No relevant relationships to disclose
S. Delaloge
No relevant relationships to disclose